Skip to content
15% off your first order15% off your first order

GLP-3R vs Semaglutide

GLP-3R and Semaglutide are both peptides studied in metabolic research and administered subcutaneously in research protocols. GLP-3R is investigated as a triple agonist at the GLP-1, GIP, and glucagon receptors, while Semaglutide is a long-acting GLP-1 receptor agonist with structural modifications that extend its half-life. The central mechanistic difference is breadth of receptor engagement: GLP-3R adds GIP and glucagon activity, the latter studied for a possible contribution to energy expenditure. GLP-3R has been studied for body weight reduction in obesity, glycemic control in type 2 diabetes, and liver fat. Semaglutide has been studied for weight loss, gastric emptying, satiety signaling, and pharmacokinetics, and a Semaglutide product, Wegovy, has been described as a weight loss drug.